AnalystsAlbert LoweAlbert Lowe's Stock Forecasts
AnalystsAlbert Lowe
Sectors:
Industries:
Analyst Ranking
Top 40%
#1973 out of 4995 analysts
Average Return
+6.62%
Win Rate
56%5 out of 9
Risk vs Reward
Poor
Good
Albert Lowe's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Opus Genetics IncIRD | +62.20% | $0.71 | $1.15 | 2025-04-10 - 2025-08-22 | Buy |
Skye Bioscience IncSKYE | +46.22% | $2.25 | $3.29 | 2025-03-20 - 2025-08-22 | Buy |
Lineage Cell Therapeutics IncLCTX | +42.53% | $0.87 | $1.24 | 2024-08-19 - 2025-08-19 | Buy |
Cardiff Oncology IncCRDF | +9.95% | $2.11 | $2.32 | 2024-09-05 - 2025-08-22 | Buy |
Neurogene IncNGNE | +8.52% | $18.42 | $19.99 | 2025-06-16 - 2025-08-22 | Buy |
Albert Lowe Analyst Color
Get additional color on Albert Lowe's coverage of popular stocks
Albert Lowe's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Neurogene IncNGNE | 1 | Buy | $50.00 | +150.13% | Initiates Coverage On | 2 months ago |
Atossa Therapeutics IncATOS | 1 | Buy | $4.00 | +414.80% | Initiates Coverage On | 3 months ago |
Opus Genetics IncIRD | 1 | Buy | $6.00 | +421.74% | Initiates Coverage On | 4 months ago |
Skye Bioscience IncSKYE | 2 | Buy | $14.00 | +325.53% | Maintains | 5 months ago |
Sab Biotherapeutics IncSABS | 1 | Buy | $11.00 | +401.14% | Initiates Coverage On | 10 months ago |
Cardiff Oncology IncCRDF | 1 | Buy | $8.00 | +244.83% | Initiates Coverage On | a year ago |
Lineage Cell Therapeutics IncLCTX | 1 | Buy | $4.00 | N/A | Initiates Coverage On | a year ago |
Pmv Pharmaceuticals IncPMVP | 1 | Buy | $6.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.